NCT04566237

Brief Summary

Cataract is the opacification of the lens. Usually cataract occurs slowly, causing progressive vision loss over several months or years. In ophthalmic clinical practice, repeated objective quantitative measurements of lens opacity may be necessary to document its progression and support a surgical indication. The subjective methods of evaluating the opacification of the lens have limitations, in particular due to the lack of reproducibility between observers. Thus, innovative objective techniques with precise and reproducible cataract classification results have been developed, such as the Objective Scatter Index (OSI) on the Optical Quality Analysis System (OQAS), Visiometrics SL in 2010 and, more recently, Average Lens Density (ALD) on the IOLMaster® 700 device. Cataract is diagnosed as mature when the OSI is ≥ 2 and / or when the ALD is ≥ 74 pixel units. Vitrectomy is a surgery of the posterior segment of the eye indicated for retinal detachment, epimacular membranes, macular holes, vitreous hemorrhage. The incidence of post-vitrectomy cataract varies among studies, and the methodology is often retrospective. Age has already been identified as a risk factor for progression since in a study of 28 eyes of patients under 50 years old, only 7% developed cataracts secondarily, compared to 79% in the 'over 50' group. To date, there is no prospective study describing the progression kinetics of lens opacification according to precise and reproducible quantitative objective criteria in patients treated by vitrectomy. It also involves confirming the age and preoperative lens status as a risk factor for postoperative cataract progression.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 17, 2020

Completed
4 days until next milestone

Study Start

First participant enrolled

September 21, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 28, 2020

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2024

Completed
Last Updated

February 13, 2025

Status Verified

February 1, 2025

Enrollment Period

4.2 years

First QC Date

September 17, 2020

Last Update Submit

February 11, 2025

Conditions

Keywords

Objective Scatter Index (OSI)Optical Quality Analysis System (OQAS)Average Lens Density (ALD)IOLMaster® 700

Outcome Measures

Primary Outcomes (1)

  • Change in ALD value between baseline and 12 months after the intervention

    ALD value : quantitative variable expressed in pixel units

    Baseline and 12 months after vitrectomy

Study Arms (1)

24 months follow up after vitrectomy

EXPERIMENTAL

Objective Scatter Index (OSI) and Average Lens Density (ALD) at inclusion, then 3 months, 12 months and 24 months after vitrectomy

Procedure: Objective Scatter Index (OSI)Procedure: Average Lens Density (ALD)

Interventions

On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy

24 months follow up after vitrectomy

on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy

24 months follow up after vitrectomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient over 18 years old
  • Indication for unilateral 3-way vitrectomy for retinal detachment, macular hole, epiretinal membrane, vitreous hemorrhage
  • Bilateral phakic patient

You may not qualify if:

  • Vitrectomy combined with cataract surgery
  • Pregnant or breastfeeding woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Fondation A. de Rothschuld

Paris, 75019, France

Location

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Study Officials

  • Raphaël LEJOYEUX, MD

    Hôpital Fondation A. de Rothschild

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2020

First Posted

September 28, 2020

Study Start

September 21, 2020

Primary Completion

December 12, 2024

Study Completion

December 12, 2024

Last Updated

February 13, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations